Medronic’s Resolute Integrity tops Abbott’s Xience | ACC 2016 roundup

Medtronic’s Resolute Integrity stent tops Abbott’s Xience in Propel all-comers study

---

Results from the Propel all-comers trial comparing Medtronic‘s (NYSE:MDT) Resolute Integrity drug-eluting stent showed it to be superior to the Xience stent made by rival Abbott (NYSE:ABT).

The 1-year study followed 800 patients from the Propel trial who were treated with the Resolute Integrity device, comparing their results with data from 1,142 Xience patients from the Resolute all-comers study.

For the primary outcome, target lesion failure at 12 months, patients treated with the zotarolimus-eluting Resolute Integrity showed a 4.3% TLF rate, compared with 8.5% for the Xience arm.

All lesions were successfully treated and the procedural success rate was 99%.

“At 12 months, the incidence of clinical events was low in all patients and also across various subgroups,” the researchers found. “The Resolute Integrity stent with the continuous sinusoidal technology had improved deliverability and excellent clinical outcomes.”

The post Medronic’s Resolute Integrity tops Abbott’s Xience | ACC 2016 roundup appeared first on MassDevice.

from MassDevice http://ift.tt/1MbmMjU